18 results with keyword: 'bortezomib plus melphalan prednisone initial treatment multiple myeloma'
At a median follow-up of 16.3 months, 45 patients in the bortezomib group and 76 in the control group had died (hazard ratio in the bortezomib group, 0.61; P = 0.008), indicating
N/A
In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed mul- tiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of
N/A
Thirty patients with re- lapsed or refractory MM were enrolled; 20 patients (67%) achieved a partial re- sponse (PR) including 13 patients (43%) who achieved at least a very good
N/A
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma
N/A
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple
N/A
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and
N/A
Based on the results of the Velcade as Initial Standard Therapy in Multiple Myeloma (VISTA) study, which showed a significant difference between bortezomib plus melphalan
N/A
Bortezomib, melphalan, and prednisone versus bort- ezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide
N/A
Carfilzomib plus melphalan and prednisone (CMP) is a promising combination therapy for the treatment of elderly patients with newly diagnosed multiple myeloma: results of a phase
N/A
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Phase 3 study (CLARION) of car filzomib,
N/A
TNT was similar between patients with high-risk versus standard-risk cytogenetics (median 24.1 v 27.4 months; HR, 1.478; P ⫽.17);survivalfromstartof subsequent therapy appeared
N/A
A Prospective, Multicenter, Randomized, Trial of bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide Prednisone (VTP) as Induction Therapy Followed
N/A
Our findings show that the oral combination of melphalan, prednisone, and thalidomide is more effective than standard treatment for newly diagnosed multiple myeloma.. This advantage
N/A
The role of bortezomib in combination with MP was examined in the large Phase III VISTA (VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan
N/A
This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine
N/A
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. Waage A, Gimsing P,
N/A
The addition of daratumumab to the standard combination treatment of bortezomib, melphalan and prednisone in untreated MM patients resulted in a
N/A